<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5568">
  <stage>Registered</stage>
  <submitdate>24/09/2010</submitdate>
  <approvaldate>24/09/2010</approvaldate>
  <nctid>NCT01209221</nctid>
  <trial_identification>
    <studytitle>A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers</studytitle>
    <scientifictitle>A Phase 1 Placebo-controlled, Randomized, Observer-blind Combined Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5271983 in Healthy Subjects.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NP25342</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo - MAD
Treatment: drugs - Placebo - SAD
Treatment: drugs - RO5271983 - MAD
Treatment: drugs - RO5271983 - SAD

Experimental: 1 - 

Experimental: 2 - 

Placebo Comparator: 3 - 

Placebo Comparator: 4 - 


Treatment: drugs: Placebo - MAD
Once or twice daily doses of matching placebo to RO5271983 for 14 days

Treatment: drugs: Placebo - SAD
Single dose of matching placebo to RO5271983 for up to 3 periods

Treatment: drugs: RO5271983 - MAD
Once or twice daily doses of RO5271983 for 14 days

Treatment: drugs: RO5271983 - SAD
Single dose of RO5271983 at each period (for up to 3 periods)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Single ascending dose (SAD): Pharmacokinetics (plasma concentration) of RO5271983</outcome>
      <timepoint>up to 240 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Single ascending dose (SAD): Safety (incidence of adverse events)</outcome>
      <timepoint>14 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Single ascending dose (SAD): Tolerability (e.g. vital signs)</outcome>
      <timepoint>14 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Multiple ascending doses (MAD): Pharmacokinetics (plasma concentration) of RO5271983</outcome>
      <timepoint>17 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Multiple ascending doses (MAD): Safety (incidence of adverse events)</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Multiple ascending doses (MAD): Tolerability (e.g. vital signs)</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of food on pharmacokinetics of RO5271983</outcome>
      <timepoint>up to 240 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Single ascending dose (SAD): Pharmacodynamics (blood analysis) of RO5271983</outcome>
      <timepoint>72 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Multiple ascending doses (MAD): Pharmacodynamics (blood analysis) of RO5271983</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy volunteers, 18-65 years of age

          -  Body Mass Index (BMI) between 18 and 32 kg/m2, inclusive

          -  In the SAD, females subjects must be surgically sterile or post-menopausal for the
             past year; in the MAD females may be of child-bearing potential but must use 2 methods
             of highly effective contraception</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  A history of clinically relevant cardiovascular, gastrointestinal, hepatic, renal,
             endocrine, pulmonary, neurological, psychiatric, allergic or skin disease

          -  Clinical significant abnormalities in laboratory test results

          -  Symptoms of an infectious disease including upper respiratory tract infection within
             one month of study start or a history of recurrent infections

          -  Smokers of &gt;5 cigarettes/day within 3 months prior to admission and unable to stop
             smoking during study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>82</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This placebo-controlled, randomized, observer-blind, dose-ascending study will investigate
      the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses
      of RO5271983 in healthy volunteers. Healthy volunteers will be randomized to receive either a
      single oral dose of RO5271983 or placebo in the SAD part or multiple oral doses of RO5271983
      or placebo in the MAD part. The anticipated time on study treatment is approximately 14 weeks
      for the SAD part and up to 8 weeks for the MAD part.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01209221</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>